These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 9505912)
1. Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients. Aristides M; Gliksman M; Rajan N; Davey P Heart; 1998 Jan; 79(1):12-7. PubMed ID: 9505912 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of abciximab: a Canadian hospital perspective. Zed PJ; Frighetto L; Sunderji R; Marra CA Ann Pharmacother; 1998 May; 32(5):536-42. PubMed ID: 9606473 [TBL] [Abstract][Full Text] [Related]
3. [Medico-economic evaluation of abciximab]. Le Pen C; Bonastre J; Pinton P Ann Cardiol Angeiol (Paris); 1999 Jan; 48(1):80-6. PubMed ID: 12555363 [TBL] [Abstract][Full Text] [Related]
4. [An economic assessment of the use of abciximab as a coronary angioplasty preparation in the Italian health-care context]. Lorenzoni R; Mazzotta G; Gensini GF; De Caterina R G Ital Cardiol; 1999 Mar; 29(3):269-76. PubMed ID: 10231672 [TBL] [Abstract][Full Text] [Related]
5. Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation. Dunn CJ; Foster RH Pharmacoeconomics; 1999 Dec; 16(6):711-41. PubMed ID: 10724797 [TBL] [Abstract][Full Text] [Related]
6. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. van Hout BA; Bowman L; Zelinger DJ; Simoons ML Am Heart J; 1998 Apr; 135(4):S98-106. PubMed ID: 9539500 [TBL] [Abstract][Full Text] [Related]
7. The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both? Oh PI; Cohen EA; Mittmann N; Seung SJ Can J Clin Pharmacol; 2004; 11(2):e202-11. PubMed ID: 15520474 [TBL] [Abstract][Full Text] [Related]
8. Abciximab therapy in percutaneous intervention: economic issues in the United States. Goklaney AK; Murphy JD; Hillegass WB Am Heart J; 1998 Apr; 135(4):S90-7. PubMed ID: 9539499 [TBL] [Abstract][Full Text] [Related]
11. Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands. van Hout BA; Simoons ML Eur Heart J; 1995 Nov; 16 Suppl L():81-5. PubMed ID: 8869024 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. Bakhai A; Stone GW; Grines CL; Murphy SA; Githiora L; Berezin RH; Cox DA; Stuckey T; Griffin JJ; Tcheng JE; Cohen DJ; Circulation; 2003 Dec; 108(23):2857-63. PubMed ID: 14610016 [TBL] [Abstract][Full Text] [Related]
13. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. van Hout BA; Bowman L; Zelinger DJ; Simoons ML Eur Heart J; 1998 Apr; 19 Suppl D():D59-66. PubMed ID: 9597523 [TBL] [Abstract][Full Text] [Related]
14. Murmurs from the heart (or why the stethoscope is not an economic tool). Aristides M; Gliksman M Heart; 1998 Jan; 79(1):10-1. PubMed ID: 9518073 [No Abstract] [Full Text] [Related]
15. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. Khan MM; Ellis SG; Aguirre FV; Weisman HF; Wildermann NM; Califf RM; Topol EJ; Kleiman NS J Am Coll Cardiol; 1998 Jan; 31(1):31-6. PubMed ID: 9426014 [TBL] [Abstract][Full Text] [Related]
16. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty. Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156 [TBL] [Abstract][Full Text] [Related]
17. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466 [TBL] [Abstract][Full Text] [Related]
18. Abciximab therapy in percutaneous intervention: economic issues in the United States. Goklaney AK; Murphy JD; Hillegass WB Eur Heart J; 1998 Apr; 19 Suppl D():D52-8. PubMed ID: 9597522 [TBL] [Abstract][Full Text] [Related]
19. [Use of abciximab during coronary angioplasty]. Philippe F; Montalescot G; Drobinski G; Thomas D Arch Mal Coeur Vaiss; 1997 Dec; 90(12):1645-50. PubMed ID: 9587446 [TBL] [Abstract][Full Text] [Related]
20. The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive. Mayosi BM; Latouf SE; Commerford PJ S Afr Med J; 1998 Feb; 88(2):130-1. PubMed ID: 9717492 [No Abstract] [Full Text] [Related] [Next] [New Search]